Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

NHS confirms deal with Novartis to fund treatment for rare periodic fever syndromes

NHS England has confirmed a deal with Novartis to fund a life-changing treatment for people with rare conditions which cause repeated bouts of fever, joint pain and swelling.

The drug, canakinumab, will now be available for patients with periodic fever syndromes (PFS) following negotiations as part of a major programme to ramp up access to innovative treatments.


Canakinumab modifies the immune system by turning off the inflammation process and significantly reducing the number of ‘flares’ children and adults experience.

Patients with three different types of PFS conditions will be eligible for treatment: familial Mediterranean fever, mevalonate kinase deficiency (also known as the hyperimmunoglobulinemia D syndrome), and tumour necrosis factor receptor-associated periodic syndrome (TRAPS).

There are around 168 patients in England with these diseases and around 80 per cent of these would be prescribed canakinumab.

Sir Simon Stevens, chief executive of NHS England, said: “Some illnesses affect a small number in a big way, which is why the NHS is increasingly bringing innovative, specialised and targeted treatments to people who need them.

“This latest new treatment has the potential to significantly improve the lives of children who bear the burden of bouts of crippling pain which blights lives and puts strain on families. It’s the latest in a line of major deals NHS England has successfully negotiated, which show that when drug companies play ball with the NHS, taxpayers get a fair deal and patients get cutting-edge treatments.”

More For You

Lynsey Cleland named GPhC chief standards officer

Lynsey Cleland

Pic credit: X

Lynsey Cleland named GPhC chief standards officer

The General Pharmaceutical Council (GPhC) has brought back Lynsey Cleland to lead on a number of important departments in the role of chief standards officer.

Cleland had previously held a number of senior positions at GPhC, including director of Scotland.

Keep ReadingShow less
Day Lewis celebrates 50 years of delivering care to communities

The Patel family at the unveiling of the commemorative plaque ceremony

Day Lewis celebrates 50 years of delivering care to communities

Day Lewis honoured "the people, purpose and partnerships" as it celebrated 50 years of service by unveiling a commemorative plaque at the company’s support office in Croydon.

As one of the UK’s largest independent pharmacy chains, Day Lewis has delivered trusted care to communities across the country since it was founded in 1975, by brothers Kirit and JC Patel, who was on hand to unveil the plaque.

Keep ReadingShow less
CPE said the committee’s discussions are fully shaped by pharmacy owners’ views and experiences

CPE said the committee’s discussions are fully shaped by pharmacy owners’ views and experiences

Pic credit: iStock

Pharmacy owners asked to share views on new contract and its financial implications

Pharmacy owners can share their thoughts on service developments and their financial security before the upcoming Community Pharmacy England (CPE) committee meeting to be held on June 25 and 26.

The new Community Pharmacy Contractual Framework (CPCF) was completed in March with the various service and regulatory changes still in progress.

Keep ReadingShow less
Cancer treatment impact

There have been supply issues with Creon since the summer of 2024

Pic credit: iStock

Cancer patients struggle amid digestive drug shortage

Pharmacists in the Channel Islands have revealed that there is a shortage of a drug used to support digestion in cancer patients.

Creon is a pancreatic enzyme replacement therapy (PERT), which helps people living with conditions such as cystic fibrosis, pancreatitis, and pancreatic cancer to digest food.

Keep ReadingShow less
Children at risk as vaccinations hit

Last year there were 2,911 confirmed measles cases in England

Pic credit: iStock

Children put at risk as vaccinations hit 10-year low

The UK is at risk of potentially deadly diseases amongst children after vaccination levels dropped to its lowest in ten years.

Britain remains below the 95 per cent coverage threshold recommended by the World Health Organisation (WHO) for all routine vaccines by the age of five.

Keep ReadingShow less